What Sivec Biotechnologies does

SiVEC Biotechnologies is a Fort Collins, Colorado-based, privately held biotech founded in 2018 by Dr. Lyndsey Linke and Darcy Mora. The company develops BactPac, a live biotherapeutic delivery platform built on a highly engineered bacterial strain that produces therapeutic payloads during manufacturing and delivers them to targeted tissues intracellularly. BactPac supports delivery of mRNA (including circular mRNA), siRNA, proteins and nanobodies, and CRISPR/Cas ribonucleoproteins, and is positioned as an alternative to viral vectors and lipid nanoparticles (LNPs) for tissues that are difficult to reach with existing modalities, including lung, heart, brain, liver, stomach, and bladder. SiVEC holds 35 patents related to the platform and its applications.

SiVEC operates a hybrid business model with three revenue streams: (1) out-licensing the BactPac platform to pharmaceutical and biotech partners (confirmed via the RheumaGen agreement for HLA-targeted gene editing in autoimmune disease); (2) co-development partnerships that generate milestone payments and royalties; and (3) an internal pipeline of first-in-class therapeutics. The internal pipeline comprises SVC-KRAb, a pan-RAS biotherapeutic for KRAS-driven cancers (PDAC, CRC, NSCLC) that has shown up to 80% tumor reduction in preclinical xenograft models; SVC-Survivin, an apoptosis-enhancer for survivin-expressing tumors; and SiVEC-IAV, an inhaled siRNA antiviral for influenza currently in NIH/NIAID-sponsored IND-enabling studies. The GTM is sales-led, with active outreach to CDMOs, CROs, and biopharma enterprises plus event-driven visibility at BIO International, RESI, and BioChallenge competitions.

The company has secured approximately $8 million in combined financing and non-dilutive funding, including nearly $4 million from NIH and the State of Colorado. Its 1–10 person team is supplemented by a Board of Directors and Scientific Advisory Board. SiVEC is pre-revenue, with no disclosed revenue figures, and remains pre-commercial across its pipeline.

Name

Sivec Biotechnologies

Legal name

SiVEC Biotechnologies

Website

https://sivecbiotechnologies.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

SiVEC Biotechnologies is a preclinical Colorado-based biotech developing BactPac, an engineered bacterial platform that produces and delivers mRNA, siRNA, proteins, and CRISPR/Cas payloads to tissues unreachable by viral vectors or LNPs, out-licensed to biopharma partners and applied to an internal pipeline in oncology and infectious disease.

Ownership category

akta.pro rank

Product category

Biotherapeutic Drug Delivery

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Engineered Microbial Therapeutics (synthetic biology, gene circuits) (HLAAAFAD)

akta.pro secondary industries

Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF)

Keywords

• Live biotherapeutic delivery
• Nucleic acid therapeutics
• Gene editing delivery
• Bacterial delivery platform
• RNA-based therapeutics

Headquarters

HQ city

Fort Collins

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Platform Licensing: Out-licensing the BactPac platform technology to pharmaceutical and biotech companies who need safe, tissue-targeted delivery solutions for nucleic acid and gene therapies.
2. Co-development Programs: Joint development partnerships with biotech companies to advance therapeutic programs using the BactPac platform, potentially generating milestone payments and future royalties.
3. Internal Therapeutic Pipeline: Developing proprietary first-in-class therapeutics (SVC-KRAb, SVC-Survivin, SiVEC-IAV) for cancer, respiratory, and genetic diseases.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

SiVEC develops the BactPac live biotherapeutic delivery platform, which uses engineered bacteria to produce and deliver therapeutic payloads including mRNA, siRNA, proteins/nanobodies, and CRISPR/Cas systems to targeted tissues. The company advances an internal pipeline of first-in-class therapeutics (SVC-KRAb, SVC-Survivin, SiVEC-IAV) and out-licenses the BactPac platform to biopharma partners for their own therapeutic pipelines.

Product overview

SiVEC Biotechnologies offers the BactPac live biotherapeutic delivery platform as its core technology, with a first-in-class internal pipeline and partnership-enabled external development. BactPac is a highly engineered bacterial platform that produces and delivers therapeutic cargo (mRNA, siRNA, proteins/nanobodies, CRISPR/Cas) to targeted tissues. The company is developing two lead therapeutic programs: SVC-KRAb, a pan-RAS inhibitor for KRAS-driven cancers, and SiVEC-IAV, an inhaled siRNA antiviral for influenza in IND-enabling studies. SVC-Survivin enhances chemotherapy efficacy by targeting survivin. The platform is also offered to biopharma partners for developing their own therapeutic pipelines.

Differentiator

Problem solved

Functional benefit

Brands

• BactPac: Live biotherapeutic delivery platform that uses specialized bacteria engineered to safely deliver therapeutic payloads (mRNA, siRNA, proteins/nanobodies, and CRISPR/Cas) to targeted tissues.
• SVC-KRAb
• SVC-Survivin
• SiVEC-IAV

Products and services

• BactPac Live Biotherapeutic Delivery Platform A live biotherapeutic delivery platform that uses specialized engineered bacteria to safely produce and deliver therapeutic payloads (mRNA, siRNA, proteins/nanobodies, and CRISPR/Cas systems) to targeted tissues, enabling cell-autonomous delivery and intracellular payload release. Offered to biopharma, CDMO, and CRO partners for licensing or co-development of nucleic acid and gene therapy programs.
• SVC-KRAb

Quantifiable outcome

• Up to 80% reduction in tumor volume in KRAS G12S xenograft mouse model compared to untreated controls
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

One partnership is on record.

• RheumaGencoreStrategic or Co-development PartnerLicensing and joint development partnership to advance HLA-targeted gene-editing therapies for autoimmune diseases. RheumaGen leverages SiVEC's BactPac bacterial delivery platform for scalability, streamlined manufacturing, and in vivo delivery of gene-editing payloads. Collaboration establishes co-development program for curative in-vivo therapies. As part of agreement, RheumaGen CEO Richard Freed joined SiVEC's Board of Directors.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Beam Therapeutics: Beam Therapeutics is a clinical-stage base editing company developing LNP and other delivery technologies for in vivo gene editing — a broader incumbent facing the same delivery bottleneck that BactPac is positioned to solve.
• BioNTech: BioNTech is the leading mRNA therapeutics company with proprietary LNP delivery technology — a broad incumbent that competes for partner attention in nucleic acid delivery and serves a similar customer base (CDMOs, CROs, biopharma partners).
• Intellia Therapeutics: Intellia is a clinical-stage gene editing company using CRISPR/Cas9 with LNP delivery — a broader incumbent that addresses the same customer problem (tissue-targeted nucleic acid delivery) but with a more mature platform and considerably greater capital.

Direct peers

• Synlogic: Synlogic develops synthetic biology-based engineered probiotic therapeutics designed to treat serious diseases — the closest publicly-traded peer using engineered bacteria as therapeutic delivery vehicles, directly comparable in modality and platform approach to BactPac.
• Locus Biosciences: Locus Biosciences develops engineered bacteriophage and microbial platforms (including CRISPR-payload delivery) for infectious disease and oncology — a directly comparable engineered-organism delivery peer with overlapping payloads (CRISPR/Cas) and customer base (biopharma).
• Eligo Biosciences: Eligo Biosciences develops engineered phage-based 'eligibodies' that deliver therapeutic payloads (e.g., CRISPR, antimicrobial proteins) to specific bacterial populations — a directly analogous engineered-microbe delivery platform competing with BactPac for nucleic acid and gene-editing cargo delivery.
• Actym Therapeutics: Actym Therapeutics engineers attenuated Salmonella to deliver therapeutic nucleic acids and immune-stimulating payloads to solid tumors — a directly comparable engineered-microbe therapeutic delivery company, particularly for the oncology use case BactPac targets via SVC-KRAb.
• Novome Biotechnologies: Novome Biotechnologies engineers synthetic microbial consortia for therapeutic delivery, including gene-editing payloads to the gut — a directly comparable engineered-microbe delivery platform with similar chassis-biology approach to BactPac.

Others

• Codexis: Codexis is a synthetic biology and enzyme engineering company — thematically adjacent, operating in the same synthetic biology tool ecosystem that underpins engineered microbial therapeutics and serving biopharma partners with similar enabling technologies.

Emerging players

• Revolution Medicines: Revolution Medicines is a clinical-stage oncology company developing pan-RAS inhibitors including RMC-6236 — directly comparable for the SVC-KRAb competitive benchmark and addressing the same KRAS-driven cancer indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/sivec-biotechnologies-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sivec Biotechnologies